☆ 4.7 Meeting Abstract

Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC)

ANNALS OF ONCOLOGY (2021)

Get Full Text
Add to Collection

Journal

ANNALS OF ONCOLOGY
Volume 32, Issue -, Pages S532-S532

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2021.08.908

Keywords

-

Categories

Oncology

Funding

  1. Daiichi Sankyo
  2. AstraZeneca

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.